Earlier this year, Wunderman Thompson SA announced the appointment of Tshego Tshukutswane to its executive team as group chief strategy officer. Tshukutswane joined this month succeeding Moagi Bodibe, who has taken up independent consulting.ByJessica Tennant
While StatsSA's latest figures show retail trade falling 3.5% year-on-year from 2019 to 2020, continuing a 10-month downward spiral, South Africa's retailers are starting to show signs of adapting to the needs of the changing market.
The current method of HIV/ Aids detection has a 50% false positive detection rate, which requires an individual to do follow-up tests to establish whether the initial diagnosis was accurate. This adds significantly to the cost of the current tests on the market.
Dr Ashley Pretorius
In 2011 a group of UWC researchers from the Biotechnology Department in the Science Faculty began searching for ways to improve these results. Dr Ashley Pretorius, Dr Marius Belmondo Tincho and other participating researchers reasoned that since the antimicrobial peptides (AMPs) – peptides that are part of the body’s immune defence system – had to first bind with certain viral proteins to attempt to neutralise the virus, this could be exploited to detect the virus, or specifically p24, one of the earliest HIV markers following infection.
The researchers used a technology called site-directed mutagenesis to improve the binding affinities of the top-ranked AMP to ensure a stronger binding to HIV proteins gp120 (for therapeutic purposes) and p24 (for diagnostic purposes).
The AMPs were then sent to Medical Diagnostech to develop a commercial diagnostic kit.
First of its kind
Gold nanoparticles were employed for a more accurate, convenient and easy visualisation of the test results. The kit is the first of its kind to make use of peptide (aptamer) technology rather than the traditional antibody technology.
The project has been expanded to include therapeutics as it was shown that several of the AMPs can neutralise HIV as well as inhibit the growth of several bacteria of medical importance, specifically those that have become antibiotic resistant.
Two MSc projects and one PhD project, resulting in two publications, as well as filing an international patent to protect the intellectual property produced in the project are among the results of the project, which is still in its pre-commercialisation phase.
The project also involves Professor Mervin Meyer from the UWC Nanotechnology Innovation Centre, King Abdullah University of Technology, Saudi Arabia, and Medical Diagnostech. The Technology Innovation Agency provided funding for the project.
LEGAL DISCLAIMER: This Message Board accepts no liability of legal consequences that arise from the Message Boards (e.g. defamation, slander, or other such crimes). All posted messages are the sole property of their respective authors. The maintainer does retain the right to remove any message posts for whatever reasons. People that post messages to this forum are not to libel/slander nor in any other way depict a company, entity, individual(s), or service in a false light; should they do so, the legal consequences are theirs alone. Bizcommunity.com will disclose authors' IP addresses to authorities if compelled to do so by a court of law.